131I	Iodine-131
177Lu	Lutetium-177
AE(s)	Adverse event(s)
AXL	AXL receptor tyrosine kinase
bid	Twice daily
CVD	Cyclophosphamide–Vincristine–Dacarbazine
D1, D1–5	Day 1; Days 1 through 5
DOTATATE	DOTA-Tyr3-octreotate (Lu-177 DOTATATE)
FLR/FLT3	Fms-like tyrosine kinase 3 (FLT3)
GI	Gastrointestinal
GEP-NET	Gastroenteropancreatic neuroendocrine tumor
HFS	Hand-foot syndrome
HIF-2α	Hypoxia-inducible factor 2 alpha
HR	Hazard ratio
HTN	Hypertension
IM	Intramuscular
IRB	Institutional Review Board
KIT	KIT proto-oncogene receptor tyrosine kinase (CD117)
LAR	Long-acting release (e.g., octreotide LAR)
mg/m2	Milligrams per square meter
MGMT	O6-methylguanine-DNA methyltransferase
MIBG	Meta-iodobenzylguanidine
mo	Months
MET	MET proto-oncogene receptor tyrosine kinase
NET	Neuroendocrine tumor
NIH	National Institutes of Health
ORR	Objective response rate
OS	Overall survival
PDGFR	Platelet-derived growth factor receptor
PFS	Progression-free survival
PO	By mouth (per os)
PPGL	Pheochromocytoma and Paraganglioma
PR	Partial response
PRRT	Peptide receptor radionuclide therapy
qd	Once daily
q21–28d/q28d	Every 21–28 days/every 28 days
RET	RET proto-oncogene receptor tyrosine kinase
SC	Subcutaneous
SD	Stable disease
SDHB	Succinate dehydrogenase complex iron sulfur subunit B
SI-NET	Small-intestinal neuroendocrine tumor
SSTR	Somatostatin receptor
SSA	Somatostatin analog
TKI	Tyrosine kinase inhibitor
TMZ	Temozolomide
TTP	Time to progression
VEGFR	Vascular endothelial growth factor receptor
α/β-blockade	Alpha/Beta-adrenergic blockade